Luke J King, Sarah L Ashmore, Hannah L Chapman, Collin M McKenzie, Bayley E Clarke, Sarah K Rozycki, Rodger W Rothenberger, Jared M Floch, Nageena R Khalid, Brittany L Roberts, Mildred N Bonglack, Charles R Rardin
{"title":"Surgical Site Infection After Sacral Neuromodulation: Impact of Postoperative Antibiotics.","authors":"Luke J King, Sarah L Ashmore, Hannah L Chapman, Collin M McKenzie, Bayley E Clarke, Sarah K Rozycki, Rodger W Rothenberger, Jared M Floch, Nageena R Khalid, Brittany L Roberts, Mildred N Bonglack, Charles R Rardin","doi":"10.1097/SPV.0000000000001627","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>There are limited data to guide practices to reduce surgical site infections following sacral neuromodulation; however, many surgeons prescribe prophylactic postoperative antibiotics after device implantation.</p><p><strong>Objective: </strong>The aim of the study was to compare the proportion of patients with sacral neuromodulation device-associated surgical site infections after use of prophylactic postoperative antibiotics versus none.</p><p><strong>Study design: </strong>This was a multicenter retrospective cohort study of patients undergoing sacral neuromodulation device implantation at 11 institutions from January 2014 to December 2023, comparing outcomes in patients who did versus did not receive prophylactic postoperative antibiotic treatment. The primary outcome was surgical site infection within 90 days. The proportions of surgical site infections were compared, and regression analyses were performed to identify variables associated with surgical site infection.</p><p><strong>Results: </strong>A total of 1,798 patients met inclusion criteria. Within this population, 67 surgical site infections (3.7%) were identified. Patients who received postoperative antibiotics (898/1798, 49.9%) were older (63.2 years vs 61.0 years, P < 0.001), and a greater proportion had staged procedures (57.9% vs 49.8%, P < 0.001). The proportion of surgical site infections and device explantations were not different between groups (3.6% vs 3.9%, P = 0.8) and (2.0% vs 2.8%, P = 0.2), respectively. After adjusting for age in a multivariate analysis, prophylactic postoperative antibiotic use was not associated with surgical site infections (0.98, 95% CI: 0.61-1.61, P = 0.94).</p><p><strong>Conclusions: </strong>Rates of surgical site infection following device implantation are low. Our findings suggest that the use of prophylactic postoperative antibiotics has minimal effect on reducing infection after device implantation. Further research is needed to explore underlying factors influencing this relationship.</p>","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urogynecology (Hagerstown, Md.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/SPV.0000000000001627","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Importance: There are limited data to guide practices to reduce surgical site infections following sacral neuromodulation; however, many surgeons prescribe prophylactic postoperative antibiotics after device implantation.
Objective: The aim of the study was to compare the proportion of patients with sacral neuromodulation device-associated surgical site infections after use of prophylactic postoperative antibiotics versus none.
Study design: This was a multicenter retrospective cohort study of patients undergoing sacral neuromodulation device implantation at 11 institutions from January 2014 to December 2023, comparing outcomes in patients who did versus did not receive prophylactic postoperative antibiotic treatment. The primary outcome was surgical site infection within 90 days. The proportions of surgical site infections were compared, and regression analyses were performed to identify variables associated with surgical site infection.
Results: A total of 1,798 patients met inclusion criteria. Within this population, 67 surgical site infections (3.7%) were identified. Patients who received postoperative antibiotics (898/1798, 49.9%) were older (63.2 years vs 61.0 years, P < 0.001), and a greater proportion had staged procedures (57.9% vs 49.8%, P < 0.001). The proportion of surgical site infections and device explantations were not different between groups (3.6% vs 3.9%, P = 0.8) and (2.0% vs 2.8%, P = 0.2), respectively. After adjusting for age in a multivariate analysis, prophylactic postoperative antibiotic use was not associated with surgical site infections (0.98, 95% CI: 0.61-1.61, P = 0.94).
Conclusions: Rates of surgical site infection following device implantation are low. Our findings suggest that the use of prophylactic postoperative antibiotics has minimal effect on reducing infection after device implantation. Further research is needed to explore underlying factors influencing this relationship.
重要性:指导实践减少骶神经调节后手术部位感染的数据有限;然而,许多外科医生在器械植入后开具预防性术后抗生素。目的:本研究的目的是比较术后预防性使用抗生素与未使用抗生素的患者发生骶神经调节装置相关手术部位感染的比例。研究设计:这是一项多中心回顾性队列研究,研究对象是2014年1月至2023年12月在11家机构接受骶骨神经调节装置植入的患者,比较接受和未接受预防性术后抗生素治疗的患者的结果。主要结果为90天内手术部位感染。比较手术部位感染的比例,并进行回归分析以确定与手术部位感染相关的变量。结果:共有1798例患者符合纳入标准。在这一人群中,发现67例手术部位感染(3.7%)。术后接受抗生素治疗的患者(898/1798,49.9%)年龄较大(63.2岁vs 61.0岁,P < 0.001),分阶段手术的比例较大(57.9% vs 49.8%, P < 0.001)。手术部位感染和器械解释的比例在两组间无差异(分别为3.6% vs 3.9%, P = 0.8)和(2.0% vs 2.8%, P = 0.2)。在多因素分析中调整年龄后,预防性术后抗生素使用与手术部位感染无关(0.98,95% CI: 0.61-1.61, P = 0.94)。结论:器械植入后手术部位感染发生率低。我们的研究结果表明,术后预防性抗生素的使用对减少器械植入后感染的影响微乎其微。需要进一步的研究来探索影响这种关系的潜在因素。